This year, the German Center for Infection Research (DZIF) is honouring the medical scientist and clinical virologist Prof. Ulrike Protzer for her scientific achievements. The prize is endowed with
Bitte verwenden Sie dieses Bild nur im Zusammenhang mit dieser Pressemitteilung.
While the highly infectious SARS-CoV-2 Delta variant has already become predominant in Germany and in most European nations, little was known about its spread in Africa. German Center for Infection
The intestine of a healthy person contains hundreds of different bacteria that provide efficient protection against infections. However, if the equilibrium of this community, known as the microbiota
Enterobacteria such as Escherichia coli or Klebsiella pneumoniae are dreaded hospital germs that can cause serious intestinal and urinary tract infections. The risk of infection with these pathogens
Please use the image only in conjunction with this message.
Paediatrician and DZIF scientist Dr Julia Pagel, Universität zu Lübeck, will receive EUR 50,000 to expand her research on lung diseases in infants. The prize is awarded by the North German Cluster of
Please use the image only in connection with this press release.
Increasingly insensitive to standard drugs: Multi-resistant pathogens are spreading worldwide and even in the near future could threaten the safe treatment of deadly infectious diseases. However, the
People under the age of 60 who initially received a vaccine from AstraZeneca should be given an mRNA vaccine at their second appointment. This is recommended by the German Standing Committee on
Please use this image only in conjunction with this press release.
Some cases of bloodstream infections are mild, but many have a fatal outcome – the reasons for these differences have remained in the dark despite decades of research. Researchers from the University
Please use this picture only in connection with the press release.
The clinical review of the MVA-SARS-2-S vector vaccine against COVID-19 will continue with a new version. The DZIF (German Center for Infection Research) scientists temporarily suspended the study
To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide, a new consortium of 30 partners from 13 countries has